Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Sacituzumab govitecan
Sponsor: German Breast Group
Collaborators: Gilead Sciences|Austrian Breast & Colorectal Cancer Study Group|Spanish Breast Cancer Research Group (GEICAM)|ETOP IBCSG Partners Foundation|Cancer Trials Ireland|UNICANCER